CU receives cooperative agreement to develop technological system to determine effects chemical substance agents The University of Colorado Boulder has been awarded a cooperative agreement worth up to $14.6 million from the Defense Advanced STUDIES Agency to develop a new technological program to rapidly determine how medications and biological or chemical brokers exert their effects on human cells. The project, known as the Subcellular Pan-Omics for Advanced Fast Threat Assessment, or SPARTA, will end up being carried out by an interdisciplinary CU-Boulder team led by Research Associate Professor William Aged of the chemistry and biochemistry section www.super-avana.com . DARPA – – an arm of the U.S. Division of Defense – – wants to better understand the biochemical mechanisms at work during cellular exposures to biological or chemical agents to greatly help prevent mortality during potential conflicts.
In the December 24th problem of Molecular Cell Their findings appear. The bookmarking protein, known as Mixed Lineage MLL or Leukemia, can be notorious for triggering leukemia when the gene that encodes it becomes mutated. MLL mutations are among the most common genetic aberrations in leukemia, happening in about 10 percent of leukemia instances. Related StoriesDiscovery could offer clues to how some viruses control expression of genetic materialResearchers effectively repair nerve cell harm in Alzheimer's dementiaRice scientists solve long-standing up mystery about hemophilia protein We’ve a clearer picture of what MLL normally does in healthy cells to help gene expression information to travel from parent cells to child cells, said Vakoc.